Cholecalciferol (VD3) attenuated motor deficits and dyskinesia in Hemi-Parkinsonian mice: behavioural, biochemical & electrophysiological implications
Objective: The study investigated the impacts of VD3 on behavioural indices, dopamine metabolism, DA transport, BDNF, corticostriatal neural activities and the possible mechanism of action…Blood–brain barrier breakdown in an adult mouse model of Parkinson’s disease
Objective: This study aims to evaluate the integrity of the blood-brain barrier (BBB) in parkinsonism. Background: Parkinson's disease (PD) is a neurodegenerative disorder which is…Spectrum of motor complications in advanced Parkinson’s disease: data from a large Romanian case series evaluated for suitability for device aided therapy
Objective: The objective was to describe the spectrum of motor complications in a large cohort of patients with advanced Parkinson’s Disease (APD) who received at…Contribution of pedunculopontine nucleus cholinergic neurons to L-DOPA-induced dyskinesia and PD motor deficits in hemi-parkinsonian rats
Objective: To determine if chemogenetic and pharmacological modulation of pedunculopontine nucleus (PPN) cholinergic neurons can alter L-DOPA-induced dyskinesia and gait deficits in hemi-parkinsonian rats. Background:…Cortical gamma oscillations as biomarkers for levodopa-induced dyskinesia
Objective: The aim of our study was to characterize cortical neuronal network activity in levodopa-induced dyskinesia in order to better understand the underlying pathophysiology and…Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data
Objective: To assess the real-world safety profile of Gocovri® (amantadine) extended release capsules one year post-launch. Background: Gocovri received FDA approval in August 2017 for…Nutritional status in patients with Parkinson’s disease and its relationship with the motor phenotype.
Objective: To determine the nutritional status in patients with Parkinson's disease and to relate it to the motor phenotype. Background: Parkinson disease (PD) is a…Serotonergic function in De Novo Parkinson’s Disease
Objective: We aimed to investigate the central serotonergic function in de novo PD and change in serotonergic function with dopaminergic medications. Background: While dopaminergic dysfunction…Mu opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease
Objective: To reappraise the role of the µ opioid receptor as a therapeutic target for L-DOPA-induced dyskinesia. Background: Parkinson’s disease (PD) is commonly treated with…Zonisamide ameliorates levodopa-induced dyskinesia via striatal cholinergic system in a rat model of Parkinson’s disease
Objective: To investigate the difference in results according to the mode of levodopa administration and the effect of zonisamide (ZNS) on striatal cholinergic system, we…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 44
- Next Page »